Clinical Trial Update: Safety, Tolerability, and Pharmacokinetics of PTI-808, PTI-801, and PTI-428 Combination Therapy in Subjects With Cystic Fibrosis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study assessing safety, tolerability, and pharmacokinetics of PTI-808, PTI-801, and PTI-428 combination in cystic fibrosis patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• PTI-428
• PTI-801
• PTI-808

Snippet

Sponsor: Proteostasis Therapeutics, Inc. | Conditions: Cystic Fibrosis | Phase 1, Phase 2 | Status: COMPLETED